Answer
Answer
Maraviroc (MVC)
Indicated in combination with other antiretrovirals for the treatment of only CCR5-tropic HIV-1 infection in patients aged ≥2 years who weigh at least 10 kg
It is imperative to test all patients for CCR5 tropism using a highly sensitive tropism assay before initiating the drug
Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on maraviroc
Dosing for patients older than 16 years
-
When given with potent CYP3A inhibitors (with or without CYP3A inducers), including protease inhibitors (except TPV/RTV): 150 mg PO BID
-
When given with nucleoside reverse transcriptase inhibitors, ENF, TPV/RTV, NVP, raltegravir (RAL), and drugs that are not potent CYP3A inhibitors or inducers: 300 mg PO BID
-
When given with potent CYP3A inducers, including EFV and ETR (without a strong CYP3A inhibitor): 600 mg PO BID
-
Additional dose adjustment required with renal impairment
Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!
Media Gallery
of
0
